Linezolid »ç¿ë ÈÄ ¹ß»ýÇÑ ¼¼·ÎÅä´Ñ ÁõÈıº 1¿¹
Serotonin syndrome associated with linezolid

Allergy Asthma & Respiratory Disease 2014³â 2±Ç 4È£ p.310 ~ p.313

Àüµ¿¼·(Jeon Dong-Sub) - µ¿¾Æ´ëÇб³ Àǰú´ëÇÐ ³»°úÇб³½Ç
³²¿µÈñ(Nam Young-Hee) - µ¿¾Æ´ëÇб³ Àǰú´ëÇÐ ³»°úÇб³½Ç
±è¼®Çö(Kim Suk-Hyun) - µ¿¾Æ´ëÇб³ Àǰú´ëÇÐ ³»°úÇб³½Ç
ÃÖ¿øÁ¾(Choi Won-Jong) - µ¿¾Æ´ëÇб³ Àǰú´ëÇÐ ³»°úÇб³½Ç
±èÀººó(Kim Eun-Bin) - µ¿¾Æ´ëÇб³ Àǰú´ëÇÐ ³»°úÇб³½Ç
ÀÌÇý¿ø(Lee Hye-Won) - µ¿¾Æ´ëÇб³ Àǰú´ëÇÐ ³»°úÇб³½Ç
³²ÈñÁÖ(Nam Hee-Joo) - µ¿¾Æ´ëÇб³º´¿ø Áö¿ªÀǾàǰ¾ÈÀü¼¾ÅÍ
¼ÛÁ¤Àº(Song Jeong-Eun) - µ¿¾Æ´ëÇб³º´¿ø Áö¿ªÀǾàǰ¾ÈÀü¼¾ÅÍ
À̼ö°É(Lee Soo-Keol) - µ¿¾Æ´ëÇб³ Àǰú´ëÇÐ ³»°úÇб³½Ç

Abstract

Serotonin syndrome (SS) is a potentially life-threatening drug reaction characterized by mental status change, increased neuromuscular tone, and autonomic instability. Linezolid, an oxazolidinone antibacterial agent, is widely used in general hospitals; however, it interacts with some serotonin agonists and may cause SS. We report a case of SS caused by linezolid, without the concomitant use of serotonin agonist. A 72-year-old patient was admitted due to recurrent wound infection of his left ankle. He developed fever, skin rash, and renal function deterioration, and blood eosinophils and liver enzymes increased after administration of vancomycin. The antibiotic was changed to linezolid against methicillin-resistant Staphylococcus aureus. Four days later, he developed agitation, fever, increased blood pressure, and tachycardia. There were no abnormal findings in laboratory and image tests, including brain and chest computed tomography suggesting the cause of his symptoms. He had not taken any serotonin agonists, including serotonin uptake inhibitors and monoamineoxidase-inhibiting antidepressants. When administration of linezolid was stopped, his symptoms improved within 24 hours and fully recovered within 2 days without additional treatments.

Ű¿öµå

Linezolid, Serotonin syndrome, Methicillin-resistant Staphylococcus aureus
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Ű¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆÇ³âµµ(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå